Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | TET3 | O43151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.48 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.48 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.48 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.48 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625869 | 0.90 | MAP4K4 (0.61) | MAP4K4ALDH1A1TET3KMT2AFBXL19 | |
| SCHEMBL10533434 | 0.86 | TET3 (0.49) | MAP4K4ALDH1A1TET3KMT2AFBXL19 | |
| SCHEMBL15349038 | 0.85 | ALDH1A1 (0.48) | MAP4K4ALDH1A1TET3KMT2AFBXL19 | |
| SCHEMBL23886618 | 0.84 | AKR1C1 (0.58) | ALDH1A1TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL14125390 | 0.83 | APP (0.44) | MAP4K4ALDH1A1HSD11B1LMNAAKR1C1 | |
| SCHEMBL20768408 | 0.81 | ALDH1A1 (0.41) | MAP4K4ALDH1A1LMNAAKR1C1TSHR | |
| SCHEMBL75310 | 0.80 | TET3 (0.61) | MAP4K4TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL29262930 | 0.80 | POLB (0.56) | ALDH1A1TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL20899550 | 0.79 | IDO1 (0.44) | MAP4K4ALDH1A1KMT2ALMNATSHR | |
| SCHEMBL15349064 | 0.79 | ALDH1A1 (0.41) | MAP4K4ALDH1A1HDAC4HSD11B1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| US-7928139-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2300427-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-7635715-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-2111399-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | Amgen Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008076427-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | MAP4K4 3589/4885ALDH1A1 2026/4885TET3 4790/4885 |
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | EGLN2, EGLN3, HIF1AN | MAP4K4 2949/4885ALDH1A1 128/4885TET3 1099/4885 |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | EGLN2, EGLN3, HIF1AN | MAP4K4 2949/4885ALDH1A1 128/4885TET3 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.